中东和非洲下一代测序 (NGS) 市场，按产品（仪器、消耗品和服务）、应用（诊断、生物标志物发现、精准医疗、药物发现、农业和动物研究等）、最终用户（制药和生物技术公司、研究中心和学术和政府机构以及医院和诊所）、国家（南非和中东及非洲其他地区）行业趋势和预测到 2029 年。
市场分析和见解：中东和非洲下一代测序 (NGS) 市场
中东和非洲下一代测序 (NGS) 市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场以 12.7% 的复合年增长率增长，预计到 2029 年将达到 7.9118 亿美元。下一代测序 (NGS) 研究活动的增加成为下一代测序 (NGS) 市场增长的驱动力。
高通量测序，被广泛认为是“下一代”测序 (NGS)，由于众多技术和功能的发展，现已融入常规临床实践，而早期的方案依赖于在临床病理学典型工作流程之外采集的样本，标准福尔马林固定、石蜡包埋样本，可更经常地用作 NGS 的起始材料。此外，正在积累用于分析和解释 NGS 数据的方案以及知识库，使临床医生能够在患者护理点更轻松地根据基因组信息采取行动。用于诊断慢性疾病的下一代测序产品种类繁多，满足了医疗机构的需求。技术进步的加快导致市场上开发出高效的下一代测序 (NGS)。
推动下一代测序（NGS）市场增长的主要因素是下一代测序在药物开发中的应用以及主要参与者提供的广泛产品组合，而阻碍下一代测序（NGS）市场增长的因素包括下一代测序产品的高成本和产品召回。
下一代测序 (NGS) 市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和下一代测序 (NGS) 市场情景，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您创建收入影响解决方案以实现您的预期目标。
下一代测序 (NGS) 市场范围和市场规模
下一代测序 (NGS) 市场根据产品、应用和最终用户进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据产品，中东和非洲下一代测序 (NGS) 市场分为仪器、耗材和服务。2022 年，仪器部分将主导下一代测序 (NGS) 市场，因为各公司正试图通过在这些地区销售产品来扩展业务，这是占据主导地位的原因。
- 根据应用，中东和非洲下一代测序 (NGS) 市场细分为诊断、药物发现、生物标志物发现、精准医疗、农业和动物研究。2022 年，诊断领域将主导中东和非洲下一代测序 (NGS) 市场，因为这些地区的疾病患病率很高，而这些国家使用 NGS 进行诊断的比例很低
- 根据最终用户，中东和非洲下一代测序 (NGS) 市场细分为医院和诊所、研究中心和学术及政府机构、制药和生物技术公司。2022 年，研究中心和学术及政府机构将在中东和非洲下一代测序 (NGS) 市场占据主导地位，因为这些公司的研究与了解非洲基因的非洲机构合作，而非洲基因在该领域占据主导地位
下一代测序 (NGS) 市场国家级分析
对下一代测序 (NGS) 市场进行了分析，并按上述国家、产品、应用和最终用户提供了市场规模信息。
下一代测序 (NGS) 市场报告涵盖的国家包括南非和中东及非洲其他地区。
由于医院和诊所使用下一代技术，该地区南非的诊断领域预计将在 2022 年至 2029 年的预测期内以最高的增长率增长。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了中东和非洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。
主要市场参与者不断增加的战略活动提高了对下一代测序 (NGS) 治疗的认识，从而推动了下一代测序 (NGS) 市场的市场增长。
下一代测序 (NGS) 市场还为您提供每个国家特定市场增长的详细市场分析。此外，它还提供有关市场参与者战略及其地理分布的详细信息。数据适用于 2011 年至 2020 年的历史时期。
竞争格局和下一代测序 (NGS) 市场份额分析
下一代测序 (NGS) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用主导地位、技术生命线曲线。以上提供的数据点仅与公司对下一代测序 (NGS) 市场的关注有关。
从事下一代测序 (NGS) 的一些主要公司包括 Agilent Technologies, Inc.、ThermoFisher Scientific, Inc.、QIAGEN、Illumina, Inc.、Bio-Rad Laboratories, Inc.、Roche Sequencing（F. Hoffman La Roche 的子公司）、BGI（BGI 集团的子公司）、Oxford Nanopore Technologies plc、MACROGEN CO., LTD.、DNASTAR、Geneious、Partek, Incorporated、PerkinElmer Inc.、Takara Bio Inc.、bioMérieux SA 以及其他国内参与者。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。
全球各地的公司也签订了许多合同和协议，这也加速了下一代测序（NGS）市场的发展。
例如，
- 2021 年 2 月，赛默飞世尔科技公司宣布其在年度 CMO 领导力奖中获得六个奖项。该奖项由 Life Science Leader 和 Outsourced Pharma 颁发，旨在表彰生物制药和生物技术公司评选出的顶级合同制造合作伙伴。据估计，这一认可有望加强公司在中东和非洲市场的影响力，并在未来几年推动公司的增长。
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在下一代测序 (NGS) 市场的影响力，这也为组织的利润增长带来了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PESTEL'S ANALYSIS
3.2 PORTER'S FIVE FORCES MODEL
4 REGULATIONS OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 DECREASE IN THE COST OF GENETIC SEQUENCING PER BASE
5.1.2 INCREASE IN THE ADOPTION OF GENOME-FOCUSED PHARMACOLOGY
5.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER
5.1.4 USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT
5.1.5 INCREASED TREND TOWARDS PERSONALIZED MEDICATION
5.2 RESTRAINTS
5.2.1 HIGH COST OF INSTRUMENT
5.2.2 DIFFICULTY IN CLINICAL NGS DATA ANALYSIS
5.2.3 CYBER SECURITY CONCERN IN GENOMICS
5.3 OPPORTUNITIES
5.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
5.3.2 PRODUCT APPROVAL IN RECENT YEARS
5.3.3 ADVANCEMENT IN NGS TECHNOLOGY
5.4 CHALLENGES
5.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS
5.4.2 CHALLENGES FOR IMPLEMENTING NGS IN THE CLINICAL LAB
6 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) HEALTHCARE INDUSTRY
6.1 IMPACT ON PRICE
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
6.5 CONCLUSION
7 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 HISEQ SERIES
7.2.2 MISEQ SERIES
7.2.3 ION TORRENT
7.2.4 PACBIO RS II
7.2.5 SEQUEL SYSTEM
7.2.6 SOLID
7.2.7 OTHERS
7.3 CONSUMABLE
7.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT
7.3.2 SAMPLE PREPARATION CONSUMABLES
7.3.3 OTHERS
7.4 SERVICES
7.4.1 SEQUENCING SERVICES
7.4.2 DATA MANAGEMENT
8 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DIAGNOSTICS
8.3 BIOMARKER DISCOVERY
8.4 PRECISION MEDICINE
8.5 DRUG DISCOVERY
8.6 AGRICULTURE & ANIMAL RESEARCH
9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER
9.1 OVERVIEW
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3 RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES
9.4 HOSPITAL & CLINICS
10 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION
10.1 MIDDLE EAST AND AFRICA
10.1.1 SOUTH AFRICA
10.1.2 REST OF MIDDLE EAST AND AFRICA
11 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
12 COMPANY PROFILING
12.1 ILLUMINA, INC.
12.1.1 COMPANY SNAPSHOT
12.1.2 REVENUE ANALYSIS
12.1.3 COMPANY SHARE ANALYSIS
12.1.4 SWOT ANALYSIS
12.1.5 PRODUCT PORTFOLIO
12.1.6 RECENT DEVELOPMENTS
12.2 BGI (A SUBSIDIAIRY OF BGI GROUP) (2021)
12.2.1 COMPANY SNAPSHOT
12.2.2 REVENUE ANALYSIS
12.2.3 COMPANY SHARE ANALYSIS
12.2.4 SWOT ANALYSIS
12.2.5 PRODUCT PORTFOLIO
12.2.6 RECENT DEVELOPMENT
12.3 THERMO FISHER SCIENTIFIC INC.
12.3.1 COMPANY SNAPSHOT
12.3.2 REVENUE ANALYSIS
12.3.3 COMPANY SHARE ANALYSIS
12.3.4 SWOT ANALYSIS
12.3.5 PRODUCT PORTFOLIO
12.3.6 RECENT DEVELOPMENTS
12.4 QIAGEN
12.4.1 COMPANY SNAPSHOT
12.4.2 REVENUE ANALYSIS
12.4.3 COMPANY SHARE ANALYSIS
12.4.4 SWOT ANALYSIS
12.4.5 PRODUCT PORTFOLIO
12.4.6 RECENT DEVELOPMENTS
12.5 AGILENT TECHNOLOGIES, INC.
12.5.1 COMPANY SNAPSHOT
12.5.2 REVENUE ANALYSIS
12.5.3 COMPANY SHARE ANALYSIS
12.5.4 SWOT ANALYSIS
12.5.5 PRODUCT PORTFOLIO
12.5.6 RECENT DEVELOPMENT
12.6 OXFORD NANOPORE TECHNOLOGIES
12.6.1 COMPANY SNAPSHOT
12.6.2 PRODUCT PORTFOLIO
12.6.3 RECENT DEVELOPMENTS
12.7 BIO-RAD LABORATORIES, INC.
12.7.1 COMPANY SNAPSHOT
12.7.2 REVENUE ANALYSIS
12.7.3 PRODUCT PORTFOLIO
12.7.4 RECENT DEVELOPMENTS
12.8X GENOMICS
12.8.1 COMPANY SNAPSHOT
12.8.2 REVENUE ANALYSIS
12.8.3 PRODUCT PORTFOLIO
12.8.4 RECENT DEVELOPMENTS
12.9 BIOMÉRIEUX SA
12.9.1 COMPANY SNAPSHOT
12.9.2 REVENUE ANALYSIS
12.9.3 PRODUCT PORTFOLIO
12.9.4 RECENT DEVELOPMENT
12.1 DNASTAR
12.10.1 COMPANY SNAPSHOT
12.10.2 PRODUCT PORTFOLIO
12.10.3 RECENT DEVELOPMENT
12.11 GENEIOUS
12.11.1 COMPANY SNAPSHOT
12.11.2 PRODUCT PORTFOLIO
12.11.3 RECENT DEVELOPMENTS
12.12 GENEWIZ, FROM AZENTA LIFE SCIENCES
12.12.1 COMPANY SNAPSHOT
12.12.2 REVENUE ANALYSIS
12.12.3 PRODUCT PORTFOLIO
12.12.4 RECENT DEVELOPMENTS
12.13 HAMILTON COMPANY
12.13.1 COMPANY SNAPSHOT
12.13.2 PRODUCT PORTFOLIO
12.13.3 RECENT DEVELOPMENT
12.14 MACROGEN, INC.
12.14.1 COMPANY SNAPSHOT
12.14.2 REVENUE ANALYSIS
12.14.3 PRODUCT PORTFOLIO
12.14.4 RECENT DEVELOPMENT
12.15 NEW ENGLAND BIOLABS
12.15.1 COMPANY SNAPSHOT
12.15.2 PRODUCT PORTFOLIO
12.15.3 RECENT DEVELOPMENT
12.16 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
12.16.1 COMPANY SNAPSHOT
12.16.2 REVENUE ANALYSIS
12.16.3 PRODUCT PORTFOLIO
12.16.4 RECENT DEVELOPMENTS
12.17 PARTEK, INCORPORATED
12.17.1 COMPANY SNAPSHOT
12.17.2 PRODUCT PORTFOLIO
12.17.3 RECENT DEVELOPMENT
12.18 PERKIN ELMER INC. (2021)
12.18.1 COMPANY SNAPSHOT
12.18.2 REVENUE ANALYSIS
12.18.3 PRODUCT PORTFOLIO
12.18.4 RECENT DEVELOPMENTS
12.19 ROCHE SEQUENCING (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
12.19.1 COMPANY SNAPSHOT
12.19.2 REVENUE ANALYSIS (PARENT COMPANY)
12.19.3 PRODUCT PORTFOLIO
12.19.4 RECENT DEVELOPMENTS
12.2 TAKARA BIO INC.
12.20.1 COMPANY SNAPSHOT
12.20.2 REVENUE ANALYSIS
12.20.3 PRODUCT PORTFOLIO
12.20.4 RECENT DEVELOPMENTS
13 QUESTIONNAIRE
14 RELATED REPORTS
表格列表
TABLE 1 NEXT GENERATION SEQUENCING COST PER SAMPLE
TABLE 2 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA DRUG DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA AGRICULTURE & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA HOSPITAL & CLINICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 27 SOUTH AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 28 SOUTH AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 29 SOUTH AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 30 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 31 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 REST OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION
FIGURE 11 WISE PORTFOLIO OFFERED BY MAJOR PLAYERS AND USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET IN 2021 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET
FIGURE 14 DECREASE IN COST OF PER BASE SEQUENCING
FIGURE 15 USE OF NSG IN DRUG DEVELOPMENT
FIGURE 16 REVENUE OF THE COMPANY AGILENT TECHNOLOGIES, INC.
FIGURE 17 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2021
FIGURE 18 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 19 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 20 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2021
FIGURE 22 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 24 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2021
FIGURE 26 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 28 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: SNAPSHOT (2021)
FIGURE 30 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021)
FIGURE 31 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 32 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 33 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT (2022-2029)
FIGURE 34 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
